Skip to main content

Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Adicet to Host R&D Webcast Event on Thursday, November 10, 2022 at 9:00am EST

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first in class, allogeneic chimeric antigen receptor (CAR) and adaptor (CAd) gamma delta T cell therapies today announced four preclinical abstract poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting taking place November 8-12, 2022 in Boston, MA.

Poster Presentations:

Abstract Title: Innate-Enhanced Chimeric Adaptors (CAd): A Newly-Described Approach for Augmenting Potency of γδ T Cell Immunotherapy

Poster/Abstract Number: 198

Presenting Author: Marissa Herrman, Ph.D.

Date/Time: November 11, 2022 from 9:00am – 9:00pm EST

Title: Preclinical Discovery and Characterization of Allogeneic anti-PSMA γδ CAR T Therapy for Prostate Cancer

Poster/Abstract Number: 203

Presenting Author: Nitya S. Ramadoss, Ph.D.

Date/Time: November 10, 2022 from 9:00am – 9:00pm EST

Abstract Title: Allogeneic “off-the-shelf” γδ T cells modified with CD27- containing CAR for targeting CD70+ cancers

Poster/Abstract Number: 246

Presenting Author: Kevin P. Nishimoto, Ph.D.

Date/Time: November 11, 2022 from 9:00am – 9:00pm EST

Abstract Title: Preclinical Discovery and Evaluation of Allogeneic “off-the-shelf” γδ CAR T Cells Targeting B7-H6+ Tumors

Poster/Abstract Number: 247

Presenting Author: Kevin P. Nishimoto, Ph.D.

Date/Time: November 10, 2022 from 9:00am – 9:00pm EST

The abstracts will be available in a Journal for ImmunoTherapy of Cancer (JITC) supplement, which will be published on Monday, November 7 at 8:00am EST on www.sitcancer.org.

R&D Webcast

Adicet will host an R&D webcast presentation on Thursday, November 10, 2022 at 9:00am EST to provide an overview of its R&D pipeline.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic chimeric antigen receptor (CAR) and adaptor (CAd) gamma delta T cell therapies engineered to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.